|
Protein measurement
|
0.100 |
GeneticVariation
|
group |
GWASDB |
A genome-wide association study of circulating galectin-3.
|
23056639 |
2012 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
A total of 862 mother-child pairs with information on maternal diet and ≥1 offspring asthma data points were included.
|
31826246 |
2020 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Weight status was determined at baseline and asthma incidence was defined as ≥2 asthma encounters and ≥1 asthma prescriptions.
|
31469258 |
2019 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Using data from the National Health and Nutrition Examination Survey from 2001 to 2010, we examined vitamin D insufficiency and (1) current asthma or wheeze in 10,860 children (6-17 years) and 24,115 adults (18-79 years) and (2) lung function in a subset of participants.
|
27913247 |
2018 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Asthma incidence was defined as ≥2 encounters with a diagnosis of asthma and ≥1 asthma controller prescription.
|
30478238 |
2018 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our main outcomes are the association between physiological, behavioural and environmental data and (1) the loss of asthma control and (2) the occurrence of asthma exacerbations.
|
28119390 |
2017 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Asthma was defined as physician-diagnosed asthma and ≥1 episode of wheeze in the previous year.
|
29173444 |
2017 |
|
Asthma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Home dust mite allergen levels (<10 or ≥10 μg/g dust) were assessed at baseline, and (≥1) severe asthma exacerbation (emergency department visit or hospitalization for asthma in the first trial year) served as the disease severity outcome.
|
25913104 |
2015 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Methods- We selected subjects enrolled in a stroke cohort study who presented within 6 hours of onset and had baseline and ≥1 follow-up brain computed tomography scans available.
|
31818229 |
2020 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
Older patients, individuals followed in diabetological practices, people receiving antihyperglycemic medications, and those affected by chronic conditions (i. e. hypertension, renal complications, or neuropathy) displayed higher odds of receiving≥2 BP and≥1 eGFR tests, whereas patients with a diabetes duration of>1 year displayed lower odds.
|
29529689 |
2019 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
The exposure of interest was referral for pre-exercise stress testing determined by an algorithm requiring sedentary patients with diabetes and ≥ 1 cardiac risk factor to undergo testing.
|
30760425 |
2019 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
The exposure of interest was referral for pre-exercise stress testing determined by an algorithm requiring sedentary patients with diabetes and ≥ 1 cardiac risk factor to undergo testing.
|
30760425 |
2019 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
Older patients, individuals followed in diabetological practices, people receiving antihyperglycemic medications, and those affected by chronic conditions (i. e. hypertension, renal complications, or neuropathy) displayed higher odds of receiving≥2 BP and≥1 eGFR tests, whereas patients with a diabetes duration of>1 year displayed lower odds.
|
29529689 |
2019 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
The primary outcome was adherence to diabetes monitoring guidelines, defined as ≥1 retinal exam, ≥4 hemoglobin A1c (HbA1c) tests, and ≥1 dyslipidemia test during a 2-year period.
|
29211592 |
2018 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
The primary outcome was adherence to diabetes monitoring guidelines, defined as ≥1 retinal exam, ≥4 hemoglobin A1c (HbA1c) tests, and ≥1 dyslipidemia test during a 2-year period.
|
29211592 |
2018 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Patients aged ≥18 years with newly diagnosed atrial fibrillation (≤6 weeks' duration) and ≥1 stroke risk factor were eligible.
|
29861295 |
2018 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
For persons with MA and (1) a personal history or family history of thrombosis, or (2) MRI evidence of micro-vascular ischemia or of stroke, an evaluation for hypercoagulability is warranted.
|
28181217 |
2018 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Risk factors associated with subclinical spread by multivariate analysis included tumor localization on the head and neck (OR 3.28, 95% confidence interval [CI] 1.16-9.32), history of previous treatment (OR 4.18, 95% CI 1.42-12.32), age ≥65 (OR 4.45, 95% CI 1.29-15.39), and ≥1 mitoses/mm<sup>2</sup> (OR 2.63, 95% CI 1.01-6.83).
|
28139264 |
2017 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Patients ≥18yrs with newly diagnosed (≤6 weeks' duration) NVAF and ≥1 investigator-determined stroke risk factors.
|
28264833 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Here we describe the use of siRNA to downregulate choline kinase, a critical enzyme in choline phospholipid metabolism of cancer cells and tumors, and the use of (1)H MRS of cells and (1)H magnetic resonance spectroscopic imaging (MRSI) of tumors to assess the efficacy of the downregulation.
|
26530913 |
2016 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We then examined the relationship between the frequency of non-sentinel lymph node metastasis and (1) the expression level of CK19 mRNA in the sentinel lymph nodes and (2) clinico-pathological features of the primary tumor.
|
22203582 |
2013 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results led us to reconsider the current reverse remodelling paradigm and (1) to include criteria of hypertrophy reversibility in the decision algorithm used to decide timing for the operation; and (2) to modify other prevailing factors (overweight, diabetes, etc) known to maintain LV hypertrophy.
|
21586423 |
2011 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
These results led us to reconsider the current reverse remodelling paradigm and (1) to include criteria of hypertrophy reversibility in the decision algorithm used to decide timing for the operation; and (2) to modify other prevailing factors (overweight, diabetes, etc) known to maintain LV hypertrophy.
|
21586423 |
2011 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The enzyme levels were significantly higher in tumor than in normal liver tissues within each rat, and were associated with the in vivo MRSI signal of [1-(13)C]alanine and [1-(13)C]lactate after a bolus intravenous injection of [1-(13)C]pyruvate.
|
21674652 |
2011 |
|
Mental Depression
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Objective:</b> To describe the prevalence and costs of anxiety and depression among moderate-to-severe psoriasis (PsO) patients in a commercially-insured US population.<b>Methods:</b> The IBM MarketScan Commercial database was used to select adults with moderate-to-severe PsO (≥1 PsO diagnosis and ≥1 systemic or biologic medication) within each calendar year from 2014 to 2016.
|
31262226 |
2019 |